Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs

International Immunopharmacology

Volumn 17, Issue 3, 2013, Pages 814-820

  Qu, Jing ^a   Hou, Zhaohua ^a   Han, Qiuju ^a   Zhang, Cai ^a   Tian, Zhigang ^a   Zhang, Jian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Human gastric adenocarcinoma; Poly(I:C); RLRs

Indexed keywords

LIPOSOME; MELANOMA DIFFERENTIATION ASSOCIATED FACTOR 5; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN; PROTEIN BCL 2; RETINOIC ACID INDUCIBLE PROTEIN I; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TUMOR XENOGRAFT; UPREGULATION;

APOPTOSIS; BCL-2; HUMAN GASTRIC ADENOCARCINOMA; LABORATORY OF GENETICS AND PHYSIOLOGY 2; LGP2; MDA-5; MELANOMA DIFFERENTIATION ASSOCIATED FACTOR 5; POLY(I:C); POLYINOSINIC-POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE GENE I-LIKE RECEPTORS; RETINOIC ACID-INDUCIBLE GENE I; RIG-I; RLRS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DEAD-BOX RNA HELICASES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; POLY I-C; RECEPTORS, RETINOIC ACID; RNA HELICASES; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884942550     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.08.013     Document Type: Article

References (31)

1. S.R.A.L. Hamilton Pathology and Genetics of Tumours of the Digestive System 3rd ed. 2000 IARC Press Lyon 37 50
2. S.S. Kim, V.E. Ruiz, J.D. Carroll, and S.F. Moss Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma Cancer Lett 305 2011 228 238
3. Y.S. Cheng, and F. Xu Anticancer function of polyinosinic-polycytidylic acid Cancer Biol Ther 10 2011 1219 1223
4. T. Seya, T. Akazawa, J. Uehori, M. Matsumoto, I. Azuma, and K. Toyoshima Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer Anticancer Res 23 2003 4369 4376 (Pubitemid 37474889)
5. M. Matsumoto, and T. Seya TLR3: interferon induction by double-stranded RNA including poly(I:C) Adv Drug Deliv Rev 60 2008 805 812
6. L. Gitlin, W. Barchet, S. Gilfillan, M. Cella, B. Beutler, and R.A. Flavell Essential role of mda-5 in type I IFN responses to polyriboinosinic: polyribocytidylic acid and encephalomyocarditis picornavirus Proc Natl Acad Sci U S A 103 2006 8459 8464 (Pubitemid 43838477)
7. Y.M. Loo, and M. Gale Jr. Immune signaling by RIG-I-like receptors Immunity 34 2011 680 692
8. A.I. Chin, A.K. Miyahira, A. Covarrubias, J. Teague, B. Guo, and P.W. Dempsey Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance Cancer Res 70 2010 2595 2603
9. B. Salaun, I. Coste, M.C. Rissoan, S.J. Lebecque, and T. Renno TLR3 can directly trigger apoptosis in human cancer cells J Immunol 176 2006 4894 4901
10. A. Paone, D. Starace, R. Galli, F. Padula, P. De Cesaris, and A. Filippini Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism Carcinogenesis 29 2008 1334 1342
11. D. Chiron, C. Pellat-Deceunynck, M. Amiot, R. Bataille, and G. Jego TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production J Immunol 182 2009 4471 4478
12. K. Yoneda, K. Sugimoto, K. Shiraki, J. Tanaka, T. Beppu, and H. Fuke Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis Int J Oncol 33 2008 929 936
13. R. Besch, H. Poeck, T. Hohenauer, D. Senft, G. Hacker, and C. Berking Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells J Clin Invest 119 2009 2399 2411
14. B. Salaun, S. Lebecque, S. Matikainen, D. Rimoldi, and P. Romero Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13 2007 4565 4574 (Pubitemid 47219727)
15. Q. Jiang, H. Wei, and Z. Tian Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway BMC Cancer 8 2008 12
16. T. Morikawa, A. Sugiyama, H. Kume, S. Ota, T. Kashima, and K. Tomita Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma Clin Cancer Res 13 2007 5703 5709 (Pubitemid 47583894)
17. M.A. Chirigos, V. Papademetriou, A. Bartocci, E. Read, and H.B. Levy Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-l-lysine, in carboxymethylcellulose [poly-ICLC] Int J Immunopharmacol 3 1981 329 337
18. S.C.S. Martindale The Complete Drug Reference 36th ed. 2009 Pharmaceutical Press London 902 2370
19. H. Navabi, B. Jasani, A. Reece, A. Clayton, Z. Tabi, and C. Donninger A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro Vaccine 27 2009 107 115
20. S. Peng, J. Geng, R. Sun, Z. Tian, and H. Wei Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors Cancer Sci 100 2009 529 536
21. A. Komuro, and C.M. Horvath RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2 J Virol 80 2006 12332 12342 (Pubitemid 44904383)
22. T. Venkataraman, M. Valdes, R. Elsby, S. Kakuta, G. Caceres, and S. Saijo Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses J Immunol 178 2007 6444 6455 (Pubitemid 46717428)
23. T. Satoh, H. Kato, Y. Kumagai, M. Yoneyama, S. Sato, and K. Matsushita LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses Proc Natl Acad Sci U S A 107 2010 1512 1517
24. V. Del Gaizo Moore, and A. Letai BH3 profiling - measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions Cancer Lett 332 2012 202 205
25. D.L. Black Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology Cell 103 2000 367 370
26. D.P. Bartel MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116 2004 281 297
27. C.E. Samuel RNA editing minireview series J Biol Chem 278 2003 1389 1390 (Pubitemid 36801359)
28. A.S. Levine, and H.B. Levy Phase I-II trials of poly IC stabilized with poly-l-lysine Cancer Treat Rep 62 1978 1907 1912 (Pubitemid 9120849)
29. Y. Kong, L. Ruan, L. Ma, Y. Cui, J.M. Wang, and Y. Le RNA interference as a novel and powerful tool in immunopharmacological research Int Immunopharmacol 7 2007 417 426
30. E. Blanco, A. Hsiao, G.U. Ruiz-Esparza, M.G. Landry, F. Meric-Bernstam, and M. Ferrari Molecular-targeted nanotherapies in cancer: enabling treatment specificity Mol Oncol 5 2011 492 503
31. P.I. Huang, W.L. Lo, J.Y. Cherng, Y. Chien, G.Y. Chiou, and S.H. Chiou Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy Curr Gene Ther 12 2012 275 284